Cargando…
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF (V600E)-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
BACKGROUND: WNT974 is a small molecule inhibitor of Wnt signaling that specifically inhibits porcupine O-acyltransferase. This phase Ib dose-escalation study evaluated the maximum tolerated dose of WNT974 in combination with encorafenib and cetuximab in patients with BRAF ( V600E)-mutant metastatic...
Autores principales: | Tabernero, Josep, Van Cutsem, Eric, Garralda, Elena, Tai, David, De Braud, Filippo, Geva, Ravit, van Bussel, Mark T J, Fiorella Dotti, Katia, Elez, Elena, de Miguel, María J, Litwiler, Kevin, Murphy, Danielle, Edwards, Michelle, Morris, Van Karlyle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020809/ https://www.ncbi.nlm.nih.gov/pubmed/36811382 http://dx.doi.org/10.1093/oncolo/oyad007 |
Ejemplares similares
-
Encorafenib plus cetuximab for the treatment of
BRAF-V600E-mutated metastatic colorectal
cancer
por: Ros, Javier, et al.
Publicado: (2022) -
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
por: Van Cutsem, Eric, et al.
Publicado: (2019) -
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020) -
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
por: Tabernero, Josep, et al.
Publicado: (2021) -
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
por: Tabernero, J., et al.
Publicado: (2021)